Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

fosnetupitant-palonosetron

fosnetupitant-palonosetron
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Akynzeo INJECTION, INTRAVENOUS 235 mg/0.25 mg    
Comments:

Interchange to a formulary NK-1 receptor antagonist (fosaprepitant 150 mg IV or aprepitant 130 mg IV) plus 5-HT3-receptor antagonist (ondansetron 16 mg IV or palonosetron 0.25 mg IV).

Interchanged products should be determined based on cost effectiveness, insurance approval, or PAP eligibility.

 

Reviewed: May 2023 (Akynzeo)

 

Spotlight Fosnetupitant/Palonosetron (Akynzeo)

Last updated: Jul. 6, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved